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Numerous studies in humans link a nonsynonymous
genetic polymorphism (I148M) in adiponutrin (ADPN)
to various forms of fatty liver disease and liver
cirrhosis. Despite its high clinical relevance, the
molecular function of ADPN and the mechanism by
which I148M variant affects hepatic metabolism are
unclear. Here we show that ADPN promotes cellular
lipid synthesis by converting lysophosphatidic acid
(LPA) into phosphatidic acid. The ADPN-catalyzed
LPA acyltransferase (LPAAT) reaction is specific for
LPA and long-chain acyl-CoAs. Wild-type mice
receiving a high-sucrose diet exhibit substantial
upregulation of Adpn in the liver and a concomitant
increase in LPAAT activity. In Adpn-deficient mice,
this diet-induced increase in hepatic LPAAT activity
is reduced. Notably, the I148M variant of human
ADPN exhibits increased LPAAT activity leading to
increased cellular lipid accumulation. This gain of
function provides a plausible biochemical mecha-
nism for the development of liver steatosis in
subjects carrying the I148M variant.
INTRODUCTION
Excessive hepatic triacylglycerol (TG) deposition (hepatosteato-
sis) is the earliest hallmark of nonalcoholic fatty liver disease
(NAFLD), which can progress to nonalcoholic steatohepatitis
(NASH) and end-stage liver disease, i.e., cirrhosis. The high prev-
alence of fatty liver disease in developed countries and the
concomitant risk for morbidity andmortality underline the impor-
tance of a detailed characterization of the processes that regu-
late hepatic TG content. Generally, TGs provide efficient storage
for surplus fatty acids (FAs). They are synthesized through the
stepwise acylation of glycerol-3-phosphate by acyltransferases
and phosphatidic acid phosphohydrolases (Coleman, 2007;
Reue and Brindley, 2008; Yen et al., 2008). Subsequent to their
synthesis, TGs form lipid droplets (LDs), which develop in vari-Cable numbers and sizes in essentially all cell types of multicellular
organisms. Upon demand, FAs are released from TGs by enzy-
matic hydrolysis. This process, commonly named lipolysis, is
catalyzed by TG hydrolases (‘‘lipases’’) (Zechner et al., 2012).
In the liver, a precisely regulated balance between lipid synthesis
and lipolysis, lipoprotein uptake and secretion, and lipid remod-
eling and oxidation regulates the cellular TG content (Adams
et al., 2005; Marchesini et al., 2001). Perturbation of this balance
disrupts metabolic homeostasis, leading to lipodystrophies or
lipid overload. Excessive lipid storage as observed in hepato-
steatosis results in lipotoxicity, a condition associated with
insulin resistance and type 2 diabetes (Schaffer, 2003).
In a landmark study, Hobbs and colleagues reported a strong
association of a sequence variant within the human patatin-like
phospholipase domain containing A3 (PNPLA3) gene with
NAFLD (Romeo et al., 2008). The PNPLA3 gene encodes a 481
amino acid protein named adiponutrin (ADPN). The sequence
variant in PNPLA3 (rs738409 C/G) leads to an Ile to Met
exchange at amino acid position 148 of ADPN (I148M).
Numerous subsequent studies confirmed this association and
showed that the I148M polymorphism also associates with other
liver pathologies, including alcoholic liver disease and hepatic
injury (Johansson et al., 2008; Kantartzis et al., 2009; Kotronen
et al., 2009; Romeo et al., 2010b; Yuan et al., 2008). However,
themechanisms bywhich the I148M variant of ADPN contributes
to these hepatic pathologies remain unknown.
ADPN belongs to a protein family defined by the presence of
a patatin domain, which was originally discovered in patatin,
the most abundant protein of the potato tuber. Due to this struc-
tural feature and the fact that some members exhibit phospholi-
pase activity, the protein family was named patatin-like phos-
pholipase domain containing proteins (PNPLAs) (Wilson et al.,
2006). The human and murine PNPLA families consist of nine
and eight members, respectively, and exhibit diverse enzymatic
functions, including phospholipase, TG hydrolase, retinylester
hydrolase, and acyl-CoA-dependent or -independent transacy-
lase activities (Kienesberger et al., 2009). ADPN is officially
named PNPLA3 and was originally identified as an adipose
tissue-specific protein that is upregulated in genetically obese
rodents and by feeding a high-carbohydrate diet (Baulande
et al., 2001; Polson and Thompson, 2003b). Recent studies re-
vealed that ADPN is also expressed in hepatocytes when miceell Metabolism 15, 691–702, May 2, 2012 ª2012 Elsevier Inc. 691
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Figure 1. Overexpression of Adpn Results in Increased TG Synthesis
Accumulation of [1-14C] oleic acid into TGs was assessed in HepG2, CHO, and Cos-7 cells. HepG2 and CHO cells were infected with murine Adpn expressing
adenovirus, and Cos-7 cells were transfected with an expression vector encoding murine Adpn. Adenovirus or vector DNA encoding b-galactosidase (LacZ) was
used as a control. After 36 hr of infection or transfection, cells were incubated with 1 mCi/ml [1-14C] oleic acid and 400 mM oleic acid complexed to BSA for 6 hr.
Subsequently, lipids were extracted and separated by TLC. Radioactivity comigrating with the TG bandwas excised and quantified by scintillation counting. Data
are presented as mean ±SD and represent two independent experiments with each sample in triplicate. Statistical significance was determined by a two-tailed
Student’s t test, **p < 0.01, ***p < 0.001.
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ADPN Acts as Lysophosphatidic Acid Acyltransferaseare fed a high-sucrose diet (HSD) or with increase in the liver fat
content (Hoekstra et al., 2010; Huang et al., 2010). In humans,
hepatic expression of ADPN is higher than in mice and exceeds
ADPN expression in adipose tissue (Huang et al., 2010; Wilson
et al., 2006). ADPN shares the highest sequence homology
(56% amino acid identity in the patatin domain) with adipose
triglyceride lipase (ATGL, also designated PNPLA2) (Zimmer-
mann et al., 2004), the rate-limiting enzyme for TG hydrolysis in
adipose and nonadipose tissues. Consistent with the structural
similarity to ATGL, ADPN was also reported to exhibit TG hydro-
lase activity (He et al., 2010; Huang et al., 2011; Jenkins et al.,
2004; Lake et al., 2005). The physiological relevance of this
activity was questioned when Adpn deficiency in mice did not
significantly affect TG hydrolysis or TG content in adipose tissue
and liver (Basantani et al., 2011; Chen et al., 2010). Various nutri-
tional (e.g., sucrose, fructose) (Baulande et al., 2001; Polson
and Thompson, 2003b), hormonal (e.g., insulin, glucose, tri-iodo-
thyronine) (Calvo and Obregon, 2009; Kershaw et al., 2006;
Moldes et al., 2006), and pharmacological factors (e.g., troglita-
zone, lipoic acid, liver X receptor [LXR] agonists) (Huang et al.,
2010; Huong and Ide, 2008; Polson and Thompson, 2003a)
regulateADPN andATGL expression, but in most cases in oppo-
site directions. For example, lipogenic stimuli dramatically
increase ADPN expression in adipocytes (Kershaw et al., 2006;
Polson and Thompson, 2003b) and in the liver (Hoekstra et al.,
2010), whereas lipolytic stimuli induce ATGL and inhibit ADPN
expression. Furthermore, overexpression of wild-type ADPN or
the I148M variant induced TG accumulation in cultured hepato-
cytes in vitro (He et al., 2010; Qiao et al., 2011), and adenovirus-
mediated overexpression of I148M in mice liver increased
the hepatic TG content. Taken together, these findings sug-
gested that ADPN is involved in lipid synthesis rather than in
lipolysis, but the biochemical activity promoting lipid synthesis
is unknown.
Here we show that human and murine ADPN acts as nutrition-
ally regulated acyl-CoA-dependent lysophosphatidic acid acyl-
transferase (LPAAT) and that the I148M variant of ADPN exhibits
elevated LPAAT activity in comparison to the wild-type protein.
We conclude that I148M promotes hepatic lipid synthesis due
to a gain of function.692 Cell Metabolism 15, 691–702, May 2, 2012 ª2012 Elsevier Inc.RESULTS
Mouse Adpn Increases Intracellular Lipid Synthesis
In Vitro
To investigate the metabolic role of Adpn, we overexpressed the
murine protein in various cell lines (see Figure S1 online) and
determined the incorporation of radiolabeled oleic acid into TG
(Figure 1). Cells expressing b-galactosidase (LacZ) were used
as control. Expression of Adpn substantially enhanced the incor-
poration of oleic acid into TG stores of HepG2 (human hepa-
toma), CHO (Chinese hamster ovary), and Cos-7 (monkey
embryonic kidney) cells, indicating that Adpn promotes lipid
synthesis independent of the cell type used.
Purified Adpn Exhibits LPAAT Activity
To identify potential enzymatic activities of Adpn in lipid
synthesis, the murine cDNA was cloned into pCold vector, and
the recombinant protein (mAdpn) was expressed in Escherichia
(E.) coli. pCold encodes a fusion protein containing an N-terminal
His tag and a 48 kDa trigger factor (TF) for cytosolic localization
of the expressed protein. This expression system enabled us to
purify mAdpn by metal-ion affinity chromatography without use
of detergents that may interfere with potential enzymatic
activities. mAdpn fusion protein exhibited aMWof95 kDa (Fig-
ure 2A). His-tagged TF (MW53.5 kDa) was isolated under iden-
tical conditions and used as a negative control in all in vitro
experiments. To investigate whether Adpn is involved in acyl-
CoA-dependent lipid synthesis, we incubated purified mAdpn
with radiolabeled oleoyl-CoA as an acyl donor andmonoacylgly-
cerol (MG), diacylglycerol (DG), glycerol-3-phosphate, or various
lysophospholipids as acceptor molecules. Thin-layer chroma-
tography (TLC) analysis revealed that mAdpn efficiently cata-
lyzes the acyl-CoA-dependent acylation of LPA to generate
phosphatidic acid (PA) (Figure 2B). No significant acyltransferase
reactions were detected when MG, DG, glycerol-3-phosphate,
lysophosphatidyl (LP)-choline, LP-ethanolamine, LP-inositol,
and LP-serine were used as acyl-group acceptors (Figure 2B).
mAdpn enhanced the formation of PA in a dose-dependent
manner with a specific activity of 2 pmol/min$mg (2 mU/mg;
Figures 2B and 2C). Concerning FA specificity, we found that
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Figure 2. Recombinant mAdpn Possesses Lysophosphatidic Acid Acyltransferase Activity
(A) Purificationof recombinantmurineAdpn (mAdpn) andTFbymetal-ion affinity chromatography. Lane1, protein standard; lane 2, uninducedE. coli lysate; lane 3,
IPTG-induced lysate (E. coliBL21 pCold-mAdpn); lane 4, flowthrough of Ni-NTA column; lane 5, eluate of Ni-NTA column containingmAdpn; lane 6, IPTG-induced
lysate (E. coliBL21 pCold); lane 7, eluate of Ni-NTA column containing TF. (B) PurifiedmAdpn or TF (1 mg protein) was incubated with 20 mM [1-14C] oleoyl-CoA as
acyl donor in thepresenceof 100mMof various acyl acceptors (lysophosphatidic acid [LPA],MG,DG,glycerol-3-phosphate [G3P], lysophosphatidyl choline [LPC],
lysophosphatidyl ethanolamine [LPE], lysophosphatidyl inositol [LPI], or lysophosphatidyl serine [LPS]) for 10 min at 37C. Lipids were solvent extracted and
separated by TLC. Enzymatic activity was calculated from the radioactivity associated with the product band. The inset represents a phosphorimager scan of the
TLC plate showing that mAdpn is active only in the presence of oleoyl-CoA and LPA but not with other lysophospholipids. PA, phosphatidic acid. Purified TF
incubated with oleoyl-CoA and LPAwas used as a negative control (represented as TF in the inset). LPAAT activity of purifiedmAdpnwasmeasured (C) at various
protein concentrations and (D) in thepresenceof acyl-CoAswith varying fatty acid chain length.Relative LPAATactivitywasdeterminedbynormalizing the specific
activity of mAdpn (2.4 nmol/min*mg) in presence of [3H] LPA and oleoyl-CoA to 100%. Data are presented as mean ±SD and are representative of three inde-
pendent experiments with each sample in duplicate. Statistical significance was determined by a two-tailed Student’s t test, ***p < 0.001.
Cell Metabolism
ADPN Acts as Lysophosphatidic Acid Acyltransferaseoleoyl-CoA, linoleoyl-CoA, and arachidonoyl-CoA were the
preferred acyl donors, followed by palmitoyl-CoA. Essentially
no LPAAT activity was observed for acyl-CoAs with chain
lengths below 16 carbons (Figure 2D). mAdpn was unable to
utilize unactivated FAs for the LPAAT reaction (data not shown).
Thrombin cleavage to facilitate tag removal from mAdpn fusion
protein resulted in a 30% increase in LPAAT activity (Figure S2),
indicating that the presence of TF in recombinant mAdpnmoder-
ately interferes with its enzymatic activity. Taken together, these
results show that mouse Adpn is a highly substrate-specific
LPAAT.
The I148M Genetic Variants of ADPN Exhibit Increased
LPAAT Activity
Previous studies demonstrated that the I148M variant of human
ADPN is associated with fatty liver in humans (Romeo et al.,
2010a; Valenti et al., 2010). The isoleucine residue at position
148 is conserved between human and mouse enzymes. ToCinvestigate the effect of this mutation on LPAAT activity, we
generated I148M variant of the murine enzyme replacing Ile-
148 to Met by site-directed mutagenesis, and purified the over-
expressed TF fusion protein in E. coli (mI148M) as described
above (Figure 3A). The specific LPAAT activity of mI148M was
2.0-fold higher than for mAdpn (4 mU/mg; Figure 3B). Addition-
ally, mI148M retained the same substrate specificity as the
wild-type enzyme with regard to acyl-CoAs as FA donors
(Figure S3A).
Next, we tested whether human ADPN also exhibits LPAAT
activity. We expressed both the human TF fusion protein
(hADPN) and the mutated version of this protein (hI148M) in
E. coli. LPAAT activity of both hADPN and hI148M was detected
in bacterial lysates overexpressing these enzymes without puri-
fication (Figure S3B). Purified hADPN and hI148M exhibited
a higher molecular mass (MW 106 KDa) than mAdpn, which
is because the human ADPN is 97 amino acids longer than the
murine ortholog (Figure 3A). Both human protein versions wereell Metabolism 15, 691–702, May 2, 2012 ª2012 Elsevier Inc. 693
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Figure 3. LPAAT Activity of Purified Murine and Human I148M Variants
(A) Coomassie blue stain showing purified TF and recombinant mAdpn, mI148M, hADPN, and hI148M. I148M mutants were generated by site-directed muta-
genesis, purified, and analyzed for LPAAT activity in comparison to wild-type proteins. Purified proteins were detected by western blotting using anti-His
monoclonal antibody.
(B and C) (B) LPAAT activity of mAdpn and mI148M and (C) hADPN and hI148M using 1 mg of purified protein in a reaction with 20 mM [1-14C] oleoyl-CoA and
100 mM LPA. Purified TF was used as negative control with negligible LPAAT activity (<0.1 nmol PA/min*mg).
(D) Substrate specificity of recombinant hADPN and hI148M for acyl donors was measured by incubating 2 mg of partially purified proteins with 25 mM [3H] LPA
(600,000 cpm/assay) and 20 mMof various acyl-CoAs. Relative LPAAT activity was determined by normalizing the specific activity of hADPN and hI148M (4.2 and
8.1 nmol/min*mg, respectively) in the presence of [3H] LPA and oleoyl-CoA to 100%.
(E) Substrate specificity of recombinant hADPN and hI148M for acyl acceptors was measured by incubating 2 mg of partially purified proteins with 20 mM [1-14C]
oleoyl-CoA as acyl donor in the presence of 100 mM of various acyl acceptors (LPA, lysophosphatidyl choline [LPC], lysophosphatidyl ethanolamine [LPE], ly-
sophosphatidyl inositol [LPI], or lysophosphatidyl serine [LPS]). Relative LPAAT activity was determined by normalizing the specific activity of hADPN and hI148M
(as shown in Figure 3C) in the presence of LPA and [1-14C] oleoyl-CoA to 100%.
(F) Acylation of glycerol-3-phosphate (G3P) was measured by incubating 2 mg purified TF, hADPN, and hI148M with 300 mMG3P and 20 mM [1-14C] oleoyl-CoA.
Data are presented as mean ±SD and are representative of at least two independent experiments with each sample in duplicates. Statistical significance was
determined by a two-tailed Student’s t test, **p < 0.01, ***p < 0.001.
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ADPN Acts as Lysophosphatidic Acid Acyltransferasemore prone to proteolytic degradation than their mouse counter-
parts. However, despite some degradation, the specific LPAAT
activity of hADPN was higher (3 mU/mg) than for mAdpn694 Cell Metabolism 15, 691–702, May 2, 2012 ª2012 Elsevier Inc.(2 mU/mg, p% 0.05), and the specific activity of hI148M mutant
was again 2.1-fold higher than that of the wild-type enzyme (Fig-
ure 3C). This indicated a gain of function in hI148M as well as in
Cell Metabolism
ADPN Acts as Lysophosphatidic Acid AcyltransferasemI148M. The substrate specificity of hADPN and hI148M was
similar to that of the murine enzymes (Figures 3D and 3E).
Notably, however, hI148M exhibited a moderate but consistent
acyltransferase activity when glycerol-3-phosphate was used
as acyl acceptor (Figure 3F).
Steady-state kinetic analysis of LPAAT activity using purified
mAdpn revealed a KM value at 12.46 mM and a Vmax of
3.41 nmol/min*mg. KM and Vmax values of the mI148M mutant
were increased 2.6- and 2.8-fold, respectively (Figure 4A). This
indicates that the I148M mutation affects both turnover rate
and substrate binding. Since no experimental 3D structure is
available for ADPN, residues mediating LPAAT activity of ADPN
are unknown. A 3D homology model, however, revealed that
Ile148 resides in very close spatial proximity of a GXSXG-
consensus sequence containing the active serine ofmany hydro-
lases/esterases (2.5 A˚ from side chain Asp166, Figure 4B).
Ser-47 located within the GXSXG sequence of ADPN has been
shown to be essential for the TG hydrolase activity of the protein
(He et al., 2010). To test whether this domain is also relevant
for LPAAT activity of human ADPN, we generated two addi-
tional mutants of ADPN: Ser-47 to Ala (hS47A) and Cys-15,
located within the predicted oxyanion hole, to Ser (hC15S). Inter-
estingly, Ser-47 was not essential for LPAAT activity, whereas
mutation of Cys-15 led to a 65% loss of the activity (Figure 4C).
The reaction mechanism proposed for classical O-acyl- and
O-acetyltransferases implies an essential role of several motifs
(motifs I, II, III, and IV as defined by Takeuchi and Reue, 2009).
Sequence analysis of human ADPN revealed only very weak
homology to LPAATa and LPAATb (Figure S3C). Nevertheless,
we mutated two conserved amino acids in the putative motifs I
and IV: Asp-206 to Ala (hD206A) and Pro-311 to Gly (hP311G).
The hP311G mutation resulted in 67% loss of activity, whereas
the hD206A point mutation had no effect on LPAAT activity (Fig-
ure 4C). Additionally, LPAAT activity of hADPN, hC15S, hS47A,
hD206A, and hP311Gwas determined in crude bacterial lysates.
hADPN overexpression increased LPAAT activity by 95% over
the endogenous LPAAT activity observed in TF-expressing
lysates (Figure 4D). The hADPN-mediated increase in LPAAT
activity was 40% and 42% lower in hC15S- and hP311G-ex-
pressing lysates, respectively. hS47A- and hP311G-expressing
lysates exhibited LPAAT activity similar to that of hADPN lysates.
ADPN Possesses Very Low TG Hydrolase Activity
and Is Not Activated by CGI-58
TG hydrolysis is initiated by ATGL (Zimmermann et al., 2004),
which is activated by comparative gene identification-58
(CGI-58; also named a/b hydrolase domain-containing 5,
ABHD5) (Lass et al., 2006). Since ADPN exhibits high sequence
identity to ATGL and was reported to hydrolyze TG (He et al.,
2010; Jenkins et al., 2004; Lake et al., 2005), we performed TG
hydrolase assays with purified ADPN and lysates of ADPN-
expressing E. coli in the presence or absence of CGI-58. As
shown in Figure 5A, purified mAdpn and hADPN exhibited
detectable but very low TG hydrolase activity (specific activity,
8 and 10 mU/mg, respectively) in comparison to LPAAT activity
(2 mU/mg). The addition of purified murine CGI-58 (mCGI-58)
did not increase ADPN-catalyzed TG hydrolysis. Overexpression
of ADPN in E. coli or in Cos-7 cells did not result in increased TG
hydrolase activity, whereas ATGL was active and stimulatedCby CGI-58 under identical conditions (Figure 5B, Figures S4A
and S4B).
ADPN Promotes TG and Phospholipid Synthesis
in Mammalian Cells
Next, we overexpressed mAdpn and hADPN in Cos-7 cells (Fig-
ure 6A) and determined cytosolic, membrane-associated, and
LD-associated LPAAT activity. mAdpn and hADPN predomi-
nantly localized to the membrane- and LD- associated cellular
fractions, but not to the cytosolic fraction (Figure 6A), confirming
previous localization studies (He et al., 2010). Consistent with
this finding, membrane-associated LPAAT activity was
increased 2-fold with overexpression of mAdpn and hADPN
(Figure 6B), and LD-associated LPAAT activity of mAdpn and
hADPN was increased 2.2- and 2.8-fold, respectively (Fig-
ure 6C). LPAAT activity generates PA, which is an important
metabolic intermediate and precursor for both TGs and glycero-
phospholipids (PLs). In accordance to this function in lipid
synthesis, we found that the overexpression of mAdpn and
hADPN significantly increased the incorporation of radiolabeled
oleic acid into TGs and PLs by 1.5- and 1.6-fold, respectively, in
Cos-7 cells cultivated in the presence of high concentration of
glucose in the medium (Figures 6D and 6E and Figure S5A).
Overexpression of mI148M or hI148M in Cos-7 cells led to
even higher incorporation of oleic acid into TGs and PLs than
overexpression of wild-type enzymes. Separation of PLs by
TLC revealed that most of the oleic acid was incorporated
into phosphatidylcholine (Figure 6E and Figure S5B). Thus,
ADPN promotes cellular TG and PL synthesis (presumably by
increased generation of PA), and the I148M variant displays
a gain of function resulting in increased lipid synthesis.
Adpn Deficiency in Mice Results in Decreased Hepatic
LPAAT Activity but Normal TG Hydrolase Activity
In accordance with previous studies (Dubuquoy et al., 2011;
Rae-Whitcombe et al., 2010), we observed a strong increase in
AdpnmRNAexpression (25-fold) in response to aHSD (Figure 7A
and Figure S6A). To investigate whether this increase affects liver
LPAAT activity, we compared acyltransferase activities in liver
homogenates of chow- and HSD-fed wild-type and Adpn-KO
mice. In chow-fed mice, Adpn deficiency was not associated
with a change in hepatic LPAAT activity in total tissue homoge-
nates (Figure 7B). Feeding wild-type mice a HSD resulted in an
3-fold increase in total LPAAT activity in liver homogenates.
Importantly, hepatic LPAAT activity of Adpn-KO mice on HSD
was 41% lower than in HSD-fed wild-type mice. Even more
impressively, LD-associated LPAAT activity in the liver was
reduced by 42% on chow diet and by 80% on HSD in Adpn-
KO compared to wild-type mice (Figure 7C and Figure S6B).
Next, we determined whether reduced LPAAT activity affects
hepatic PA and LPA concentrations. A trend toward lower PA
and increased LPA concentrations (Figures S6C and S6D)
led to a reduction of the PA/LPA ratio in total liver lipid extracts
of Adpn-deficient mice on chow diet (p < 0.001) and HSD
(p < 0.1) (Figure 7D). Total cellular DG levels were similar in
wild-type and Adpn-deficient mice (Figure S6E). However,
when specific DG species were analyzed, we noted a marked
decrease in 34:1 DG by 40% (Figure S6F). Assuming that the
de novo lipid synthesis predominantly generates 34:1 DG, theseell Metabolism 15, 691–702, May 2, 2012 ª2012 Elsevier Inc. 695
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Figure 4. Enzyme Properties of Murine and Human ADPN Variants
(A) LPAAT activity of mAdpn and mI148M was monitored as a function of [1-14C] oleoyl-CoA concentration and kinetic parameters were calculated by Michaelis-
Menten plot using GraphPad Prism software.
(B) Structure around the putative ‘‘catalytic dyad’’ (Ser-47 and Asp-166) involved in the proposed lipase activity of ADPN. The structure was deduced from an
alignment of Leu10-Phe175 of ADPN to Leu32-Ala225 of Pat17 (PDB ID 1OWX), the best-scoring template with known 3D structure using the Phyre2 server
(Kelley and Sternberg, 2009), and PyMOL (The PyMOLMolecular Graphics System, Version 1.4.1, Schro¨dinger, LLC). Themodel reveals close spatial proximity of
Ile148 (highlighted in yellow) and Cys15 (highlighted in green) to the proposed active site (highlighted in red).
(C) LPAAT activity of hADPN and hADPNmutants with point mutations at Cys-15 to Ser (hC15S), Ser-47 to Ala (hS47A), Asp-206 to Ala (hD206A), and Pro-311 to
Gly (hP311G). Mutants were generated by site-directed mutagenesis and purified under conditions identical to those of the wild-type protein. The inset shows
a Coomassie blue-stained SDS-PAGE gel with various purified recombinant ADPN variants (2 mg protein/lane). LPAAT activity was measured using 2 mg of
purified proteins or TF as described in the Experimental Procedures.
(D) LPAAT activity was determined in bacterial total lysates (10 mg lysate protein) overexpressing TF, hADPN, or hADPN mutants. Protein overexpression was
confirmed by western blotting in bacterial total lysates using anti-His monoclonal antibody (inset). Experiments were done in duplicates and repeated twice. Data
are presented as mean ±SD. Statistical significance was determined by a two-tailed Student’s t test, **p < 0.01, ***p < 0.001.
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Figure 5. TG Hydrolase Activity of ADPN
(A) TG hydrolase activity assay using radiolabeled
triolein as substrate in the presence of 5 mg purified
TF, mAdpn, mI148M, hADPN, hI48M, and (B)
bacterial total lysates (40 mg lysate protein) over-
expressing TF, mAdpn, mI148M, hADPN, hI148M,
and strep-taggedmATGL. Assays were performed
in the absence or presence of purified mCGI-58.
Data are shown as mean ±SD and represent three
independent experiments. Statistical significance
was determined by a two-tailed Student’s t test,
*p < 0.05, ***p < 0.001. FFA, free fatty acid.
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ADPN Acts as Lysophosphatidic Acid Acyltransferasedata suggested that Adpn deficiency may affect the de novo
synthesis of TGs and PLs due to reduced provision of PA
precursor. In line with previous studies (Basantani et al., 2011;
Chen et al., 2010), Adpn deficiency in mice did not alter total liver
TG content (Figure S6G), TG hydrolase activities in WAT or liver
lysates (Figures S7A–S7D), or plasma parameters (Table S1).75
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Cos-7 cells were transfected with His-tagged pcDNA4/HisMax expression vector
loaded with 400 mMoleic acid complexed to FA-free BSA (3:1) in DMEM containin
density gradient centrifugation.
(A) Expression of recombinant proteins was determined by immunoblotting usin
fractions were detected by anti-ADRP and anti-IRE1a antibody, respectively.
(B and C) (B) LPAAT activity assay using 20 mM [1-14C] oleoyl-CoA as acyl do
total membrane protein) and (C) isolated LD fractions (20 mg of LD protein). Experim
Statistical significance was determined by a two-tailed Student’s t test, *p < 0.05
(D and E) (D) Incorporation of [1-14C] oleic acid into TGs and total PLs in Cos-7 c
proteins, in the presence of high-glucose medium. Lipids were separated by TL
choline (PC) was quantified by liquid scintillation counting. Experiments were do
experiments. Statistical significance was determined by a two-tailed Student’s
WT ADPN).
CDISCUSSION
Numerous independent studies reported a strong associa-
tion between a common human ADPN variant (I148M) and the
pathogenesis of fatty liver disease (Johansson et al., 2008;
Kotronen et al., 2009; Romeo et al., 2010b). Yet, the underlying0 4
0.5
0.6
n
*
m
g
*
***
C
0.0
0.1
0.2
0.3
.
LacZ mAdpn hADPN
n
m
o
l 
P
A
/m
in
mAdpn hADPN
LacZ
mAdpn
100
150
200
a
c
i
d
 
i
n
c
o
r
p
o
r
a
t
i
o
n
F
A
/
m
g
 
p
r
o
t
e
i
n
)
mI148M
hADPN
hI148M
**
#
*
*#
0
50
PC
[
1
-
1
4
C
]
 
o
l
e
i
c
 
 
(
n
m
o
l
 
F
AT Activity and Lipid Synthesis
encoding mouse or human ADPN and LacZ as a control. After 24 hr, cells were
g 10% FBS for 20 hr. LDs, membrane, and cytosol fractions were isolated using
g anti-His monoclonal antibody. Marker proteins for LDs and total membrane
nor and 100 mM LPA as acyl acceptor in total membrane fractions (2 mg of
ents were done in triplicate and repeated twice. Data are shown asmean ±SD.
and **p < 0.01.
ells overexpressing mouse or human ADPN or their respective I148M mutant
C and radioactivity comigrating with TGs and total PLs, and (E) phosphatidyl-
ne in duplicate and repeated thrice. The graph depicts the mean ±SD of two
t test, *p < 0.05 (compared to LacZ), #p < 0.05 (compared to mouse/human
ell Metabolism 15, 691–702, May 2, 2012 ª2012 Elsevier Inc. 697
2050
n
c
e
B
**
A
5
10
15
n
m
o
l 
P
A
/m
in
*
m
g Adpn-ko
10
20
30
40
v
e
 m
R
N
A
 a
b
u
n
d
a
n
Adpn-ko
***
KO -KO
35 WT
WT
WT
WT
0
Chow HSD
0
Chow HSD
r
e
la
t
iv
**
C
7
D
5
10
15
20
25
30
P
A
/L
P
A
 r
a
t
io
**1
2
3
4
5
6
n
m
o
l 
P
A
/m
in
*
m
g
*** p=0.1
Adpn-KO Adpn-KO
0
Chow HSD
0
Chow HSD
Figure 7. Hepatic LPAAT Activity of Wild-
Type and Adiponutrin-Deficient Mice
Five hours postfeeding, male wild-type (WT) and
Adpn-KO mice fed a chow diet or HSD were
sacrificed, and the liver was excised.
(A) Relative liver Adpn mRNA expression as
determined by RT-qPCR was normalized to
b-actin as a reference gene and compared to WT
mice fed chow diet, n = 6.
(B) LPAAT activity was determined in liver tissue
homogenates (20 mg total protein), n = 5.
(C) LD-associated LPAAT activity was determined
in freshly prepared liver LDs (10 mg LD protein).
Data are representative of three independent diet
studies, n = 4 or 5. Data are shown as mean ±SD.
Statistical significance was determined by a two-
tailed student’s t test, **p < 0.01, ***p < 0.001.
(D) Phosphatidic acid (PA) to lysophosphatidic
acid (LPA) ratio inWT and Adpn-KOmice liver lipid
extracts. Liver samples were collected from chow
diet- and HSD-fed WT and Adpn-KO mice after
2 min organ perfusion with Krebs-Henseleit Buffer
2. For the determination of LPA and PA concen-
trations, hepatic glycerophospholipids were ex-
tracted using a modified Bligh and Dyer method
(Bligh and Dyer, 1959). Lipids were quantified by
LC/MS/MS (details described in the Supplemental
Experimental Procedures), n = 6. Data are shown
as mean ±SEM. Statistical significance was
determined by post hoc analysis, ***p < 0.001.
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the present study demonstrate that purified recombinant mouse
and human ADPN exhibit acyl-CoA-dependent LPAAT activity.
The fact that increased LPAAT activity is found in crude lysates
of both bacterial (E. coli) and eukaryotic (Cos-7) expression
systems suggests that the activity is intrinsic to ADPN and not
caused by alternative proteins. This conclusion is further sup-
ported by the facts that single-point mutations in human ADPN
drastically reduced LPAAT activity and that extensive sequence
analysis of purified ADPN variants revealed no evidence for the
presence of other contaminating acyltransferases than ADPN
(data not shown). In accordance with an anabolic function, over-
expression of ADPN promotes TG and PL synthesis in cultured
cells. Together with the previously shown dietary effects on
ADPN expression in adipose tissue and liver (Baulande et al.,
2001; Hoekstra et al., 2010; Polson and Thompson, 2003b),
these results imply that ADPN is a nutritionally regulated LPAAT
participating in hepatic lipid synthesis. Importantly, the respec-
tive I148M variants of mouse and human ADPN exhibit higher
LPAAT activities than the wild-type enzymes. This gain of func-
tion provides a potential explanation for the increased suscepti-
bility of patients carrying the I148M variant to the development of
liver steatosis and NAFLD.
Previous studies assigned other biochemical activities to
ADPN, including a function as TG hydrolase (He et al., 2010;
Huang et al., 2011; Jenkins et al., 2004; Lake et al., 2005). We
confirmed this activity for mouse and human ADPN but found
that the specific TG hydrolase activity is much lower than that
for ATGL. The rather low TG hydrolase activity and the fact
that ADPN overexpression failed to decrease cellular TG levels
in vitro (Kershaw et al., 2006; Lake et al., 2005) or hepatic TG698 Cell Metabolism 15, 691–702, May 2, 2012 ª2012 Elsevier Inc.content in mice in vivo (He et al., 2010; Qiao et al., 2011) argue
against a physiological function of ADPN as a catabolic TG
lipase.
ADPN is the second member of the mammalian PNPLA family
of proteins with acyl-CoA-dependent acyltransferase activity.
Gao et al. (Gao et al., 2009; Gao and Simon, 2007) reported
that a structurally related protein, GS2 (PNPLA4), catalyzes
acyl-CoA-dependent and -independent acylation of retinol.
In the yeast Saccharomyces cerevisiae, the patatin domain-
containing yeast proteins TGL3, TGL4, and TGL5 were also
shown to possess LPAAT activity in addition to lipolytic activities
(Rajakumari and Daum, 2010). Other members of the PNPLA
family are established TG hydrolases and phospholipases.
Phospholipases of the family consistently hydrolyze the
secondary ester at the sn-2 position of PLs. ADPN also acts at
the sn-2 position of the glycerol backbone, but instead of ester
hydrolysis, it catalyzes ester formation at this position. Notably,
the enzyme is highly substrate specific for LPA and long-chain
fatty acyl-CoAs, which is similar to the substrate preference
reported for acyl-CoA acylglycerol-3 phosphate acyltransferase
2 (AGPAT2) (Takeuchi and Reue, 2009). It does not esterify other
lysophospholipids or utilize acyl-CoAs shorter than C16.
ADPN adds to a long list of known LPAAT enzymes. The
majority of the established LPAATs belong to the AGPAT family
of enzymes (Takeuchi and Reue, 2009). At least seven AGPAT
members (AGPAT1– AGPAT5, AGPAT8, and AGPAT9) mediate
acylation of lysophospholipids in an acyl-CoA-dependent
manner. The enzymes differ in substrate specificity and tissue-
specific expression profile (Agarwal et al., 2002; Beigneux
et al., 2006; Chen et al., 2008; Cortes et al., 2009; Vergnes
et al., 2006). The physiological relevance of most AGPATs
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(LPAATb). Deficiency of this enzyme causes congenital general-
ized lipid dystrophy (CGL) in humans (Agarwal et al., 2002). CGL
is an autosomal recessive disorder characterized by pronounced
lack of adipose tissue, severe hypertriglyceridemia, hepatic
steatosis, insulin resistance, and diabetes. A similar phenotype
is observed in AGPAT2-deficient mice (Cortes et al., 2009). In
these animals, severe hepatic steatosis is apparently not caused
by the compensatory action of alternative AGPATs but by
a metabolic diversion that involves the dephosphorylation of
LPA, the acylation of the resulting MG to DG by MGAT1, and
the subsequent formation of TG by acyl-CoA:diacylglycerol acyl-
transferase 2 (DGAT2). In addition to AGPATs, CGI-58 can also
act as an LPAAT independent to its ATGL coactivator function
(Ghosh et al., 2008; Gruber et al., 2010; Montero-Moran et al.,
2010). CGI-58 has no clearly defined acyltransferase domain
and is structurally not related to members of the AGPAT family
(Oberer et al., 2011). Accordingly, the enzymatic mechanism
for the acyltransferase activity is unknown.
Unexpectedly, Adpn deficiency is not associated with
a detectable metabolic phenotype in mice (Basantani et al.,
2011; Chen et al., 2010). Adpn gene knockout does not affect
TG hydrolysis, energy/glucose/lipid homeostasis, or hepatic
lipid content in mice kept on chow, high-fat, or HSDs. Consid-
ering these resounding negative results, it was concluded that
loss of ADPN does not contribute to the pathogenesis of fatty
liver disease, at least in mice. Our finding that ADPN has signif-
icant LPAAT activity is consistent with this conclusion and
suggests that liver steatosis in patients carrying the I148Mmuta-
tion is more likely to be caused by a gain-of-function effect
leading to increased TG synthesis and deposition. It is also
consonant with the observation that adenoviral overexpression
of the I148M mutant ADPN causes fatty liver in mice (He et al.,
2010). However, why the adenoviral overexpression of wild-
type ADPN does not affect hepatic TG levels (He et al., 2010)
remains unclear.
The absence of changes in the cellular lipid composition or
energy metabolism in Adpn-deficient mice (Basantani et al.,
2011; Chen et al., 2010) indicates that the Adpn-catalyzed
LPAAT activity is not essential under various dietary conditions.
We noticed a clear difference in enzyme activities as well as
a reduction in the hepatic PA/LPA ratio of Adpn-deficient mice.
That these changes did not translate into a more severe pheno-
type in Adpn-deficient mice suggests that alternative pathways
of lipid synthesis such as the MGAT1 pathway in AGPAT2-defi-
cient mice (Cortes et al., 2009) can compensate for the reduced
LPAAT reaction. Alternatively, the reduced LPAAT activity in the
liver of Adpn-deficient mice may still suffice to ensure normal TG
and PL synthesis.
The observed reduction in LD-associated LPAAT activity in
Adpn-KO mice also suggests that Adpn may facilitate PA
synthesis on LDs. Previous studies showed that other enzymes
in the biosynthetic pathway of TGs and PLs are also present
on LDs, including lipins (Valdearcos et al., 2011; Wang et al.,
2011), DGAT2 (Kuerschner et al., 2008; Stone et al., 2009),
and CTP:phosphocholine cytidylyltransferase (Krahmer et al.,
2011). This indicates that lipid synthesis may not be restricted
to the ER membrane but may also occur at least partially on
LDs. The spatial separation of synthetic pathways for identicalClipids suggests different functions for distinct lipid pools in
different organelles. The importance of LDs and lipolysis as
a platform for the generation of products participating in cardiac
peroxisome proliferator-activated receptor (PPAR) signaling
was recently shown (Haemmerle et al., 2011), and it is
conceivable that ADPN-generated PA on LDs may also affect
cellular signaling processes such as PPAR (Moolenaar et al.,
2004), mammalian target of rapamycin (TOR) (Foster, 2009), or
mitogen-activated protein kinase (MAPK) signaling (Wang
et al., 2006).
In summary, we identified a biochemical function for ADPN.
The protein acts as a LD-associated, nutritionally regulated
LPAAT. In this function, the enzyme may contribute to local lipid
synthesis and/or affect the generation of potential signaling
lipids. The I148M variant of ADPN is more active than the wild-
type enzyme, suggesting that hepatosteatosis in humans
carrying this mutation results from a gain of function and
increased hepatic TG synthesis.EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of mAdpn and hADPN
The coding sequences for mAdpn and hADPN were amplified by PCR using
Phusion DNA polymerase and primers as given in Table S2. The purified
amplicon was ligated into the bacterial expression vector pCold or the eukary-
otic expression vector pcDNA4/HisMax C. Site-directed mutagenesis was
performed using the GeneTailor Site-Directed Mutagenesis System (Invitro-
gen, Carlsbad, CA, USA). Wild-type and mutant murine and human ADPN
proteins overexpressed in E. coli were purified by metal-ion affinity column.[1-14C] Oleic Acid Incorporation in Cellular Lipids
HepG2, CHO, and Cos-7 cells were used to determine [1-14C] oleic acid
accumulation in cellular TGs. HepG2 and CHO cells were infected with adeno-
virus expressing Adpn. Cos-7 cells were transfected with expression vector
pcDNA4/HisMax C encoding Adpn. Cells were incubated with 1 mCi/ml
[1-14C] oleic acid and 400 mM oleic acid complexed to BSA for 6 hr, lipids
were extracted, and radioactivity comigrating with the TG band was quantified
by scintillation counting. Cells were lysed in 0.3 N NaOH containing 0.1% SDS
to determine the protein concentrations.Animal Studies
Adpn-KO mice were generated and bred as described previously (Basantani
et al., 2011). Plasma parameters were determined using commercially avail-
able kits. Isolation of tissue RNA and quantification by RT-qPCR followed stan-
dard laboratory procedures.
For HSD studies, male Adpn-KO mice (10 weeks old) were housed individ-
ually at 25C using a 12 hr light/dark ‘‘switch cycle.’’ After 1 week acclimatiza-
tion, mice were fed a semisynthetic diet consisting of 60% sucrose, 20%
casein, 5% cellulose, 6% mixture of minerals, 5% vitamins, cysteine, choline
chloride, and soybean oil (Ssniff, Soest, Germany) for 3 weeks (Polson and
Thompson, 2003b). Mice were killed by cervical dislocation 5 hr after the
feeding period (postmeal). Freshly dissected liver samples (0.8 g) were
used for LD isolation. Other tissues were dissected, weighed, immediately
frozen in liquid nitrogen, and stored at80C until used. All animal procedures
were carried out according to the guidelines of the Federation of European
Laboratory Animal Science and were approved by Austrian government
authorities.Enzymatic Activity Assays
LPAAT activity was measured by acylation of LPA using [1-14C] oleoyl-CoA.
Formation of radioactively labeled PA was determined in lipid extracts that
were separated by TLC (Ghosh et al., 2008). Spots comigrating with PA stan-
dard were cut and quantified by scintillation counting.ell Metabolism 15, 691–702, May 2, 2012 ª2012 Elsevier Inc. 699
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bacterial total lysates, and membrane and total lysates fraction of Cos-7 cells
as described previously (Lass et al., 2006).
Membrane- and LD-Associated LPAAT Assay in Cos-7 Cells
Cos-7 cells were transiently transfected with expression plasmids encoding
His-tagged mAdpn or hADPN. After 24 hr of transfection, cells were incubated
with 400 mM oleic acid for further 20 hr. Cells were harvested to isolate total
membrane and LD fractions. LPAAT activity was measured in the LD, cyto-
solic, and membrane fractions as described above.
Western Blotting
Cell lysates (10 mg protein), purified proteins (2 mg protein), or cell fractions
(6 mg protein) were separated by 10% SDS PAGE and transferred to polyviny-
lidene fluoride membranes (Carl Roth GmbH, Karlsruhe, Germany). The blots
were incubated with anti-His (N-terminal) monoclonal antibody (1:5,000; GE
Healthcare), anti-His (C-terminal) polyclonal antibody (1:1,000; ReliaTech,
Germany), anti-adiponutrin polyclonal antibody (1:10,000; Everest Biotech),
anti-adipophilin (ADRP) antibody (1:3,000; Progen Biotechnik), or anti-
Inositol-requiring 1a (IRE1a) monoclonal antibody (1:1,000; Cell Signaling).
For all immunoblots, appropriate horseradish peroxidase-conjugated
secondary antibodies were used. Detection was performed with enhanced
chemiluminescence (ECL plus, GE Healthcare) and exposure to X-ray film
(Hyperfilm ECL, GE Healthcare).
Lipid Extraction and Mass Spectrometry Analysis
Liver samples were collected from Adpn-KO mice on chow or HSD after 2 min
perfusion with Krebs-Henseleit Buffer 2. Lipids were extracted using a modi-
fied Bligh and Dyer procedure (Bligh and Dyer, 1959) and individual lipid
species were identified by LC/MS/MS based on their chromatographic, and
mass spectral characteristic.
Statistical Analyses
Data are presented as mean ± standard deviation (SD). Measurements in wild-
type and Adpn-KO mice were compared by Student’s unpaired t tests (two
tailed) or post hoc analysis. Data were considered statistically significant at
*p < 0.05, **p < 0.01, ***p < 0.001.SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, three tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.cmet.2012.04.008.ACKNOWLEDGMENTS
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